The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F19%3AN0000026" target="_blank" >RIV/00064190:_____/19:N0000026 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216224:14110/19:00112440 RIV/00216208:11110/19:10398517 RIV/00216208:11140/19:10398517 RIV/00669806:_____/19:10398517 RIV/00209805:_____/19:00078311
Výsledek na webu
<a href="http://dx.doi.org/10.21873/anticanres.13761" target="_blank" >http://dx.doi.org/10.21873/anticanres.13761</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.21873/anticanres.13761" target="_blank" >10.21873/anticanres.13761</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
Popis výsledku v původním jazyce
Background/Aim: The aim of our study was to assess the predictive role of primary tumour sidedness (PTS) in patients with metastatic colorectal cancer (mCRC) harbouring wild-type RAS and treated with targeted agents. Patients and Methods: The cohort included 178 patients treated with first-line chemotherapy plus cetuximab, panitumumab or bevacizumab. Results: We observed longer progression-free survival (PFS) and overall survival (OS) in patients with left-sided (L-CRC) compared to right-sided tumours (R-CRC) treated with anti-EGFR mAbs (p=0.0033 and p=0.0037), while there was no difference in patients treated with bevacizumab (p=0.076 and p=0.56). Finally, we observed longer PFS and OS in patients with L-CRC treated with anti-EGFR mAbs and those with R-CRC treated with bevacizumab compared to the reverse combination (p=0.0002 and p=0.011). Conclusion: PTS is a predictive factor for anti-EGFR mAbs, not for bevacizumab. Superior survival was observed when anti-EGFR mAbs were used for L-CRC and bevacizumab for R-CRC.
Název v anglickém jazyce
The Predictive Role of Primary Tumour Sidedness in Metastatic Colorectal Cancer Treated With Targeted Agents
Popis výsledku anglicky
Background/Aim: The aim of our study was to assess the predictive role of primary tumour sidedness (PTS) in patients with metastatic colorectal cancer (mCRC) harbouring wild-type RAS and treated with targeted agents. Patients and Methods: The cohort included 178 patients treated with first-line chemotherapy plus cetuximab, panitumumab or bevacizumab. Results: We observed longer progression-free survival (PFS) and overall survival (OS) in patients with left-sided (L-CRC) compared to right-sided tumours (R-CRC) treated with anti-EGFR mAbs (p=0.0033 and p=0.0037), while there was no difference in patients treated with bevacizumab (p=0.076 and p=0.56). Finally, we observed longer PFS and OS in patients with L-CRC treated with anti-EGFR mAbs and those with R-CRC treated with bevacizumab compared to the reverse combination (p=0.0002 and p=0.011). Conclusion: PTS is a predictive factor for anti-EGFR mAbs, not for bevacizumab. Superior survival was observed when anti-EGFR mAbs were used for L-CRC and bevacizumab for R-CRC.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
<a href="/cs/project/LO1503" target="_blank" >LO1503: BIOMEDIC</a><br>
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
ANTICANCER RESEARCH
ISSN
0250-7005
e-ISSN
1791-7530
Svazek periodika
39
Číslo periodika v rámci svazku
10
Stát vydavatele periodika
GR - Řecká republika
Počet stran výsledku
8
Strana od-do
5645-5652
Kód UT WoS článku
000488512600042
EID výsledku v databázi Scopus
2-s2.0-85072774745